Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies
Medication Detail
Teva's Severe Asthma Therapy Reslizumab Now Approved in Europe | RT
Teva Reports Two Successful Phase III Studies For Reslizumab In Asthma
Dosing and Administration
Reslizumab | Teva UK
Advisory Committee Briefing Materials: Available for Public Release
FDA accepts Biological License Application for reslizumab
Cinqair (reslizumab)- Asthma- by Saro Arakelians, PharmD- Episode # 123 - YouTube
Israeli Pharma gets FDA Approval for New Antibody against Severe Asthma | Free directory of clinics in Israel
Chest Medicine Made Easy-Dr Deepu: FDA approves Injectable drug for uncontrolled Asthma
How patients use CINQAIR® (reslizumab) Injection Cost Support Program Card
Clinical Study Protocol Distribution of Eosinophils in Asthma after Reslizumab (DEAR). A 7-week, Placebo- Controlled, Double-Bli
Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma – First Initiators and Switchers - ScienceDirect
Australian Public Assessment Report Reslizumab
Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects - Jorge Máspero, 2017
Older Patients with Asthma Do Well with Reslizumab | RT
Cinqair Reslizumab Injection
CINQAIR® (reslizumab) Injection – About Asthma Control
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
Reslizumab | New Drug Approvals
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials - The Lancet Respiratory Medicine
Brand name: Auvi-Q
Teva-Handok wins approval for anti-asthma injection < Pharma < Article - KBR
Rx Item-Cinqair (Reslizumab) 10Mg/Ml Inj Sinle Use Vial 10Ml By Teva Respiratory
Frontiers | Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?
